Cue Biopharma, Inc.(CUE)Earnings, Financials & Key Ratios
CUE•NASDAQ
$35.73
$94M mkt cap·Price updated May 7, 2026
AboutCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$27M+195.7%
- EBITDA-$23M+41.1%
- Net Income-$27M+34.6%
- EPS (Diluted)-8.40+61.1%
- Gross Margin87.33%-12.7%
- EBITDA Margin-84%+80.1%
- Operating Margin-96.67%+78.4%
- Net Margin-96.85%+77.9%
- ROE-121.11%+18.7%
- ROIC-537.56%+38.0%
- Debt/Equity0.16-68.7%
- Interest Coverage-74.29-48.3%
CUE Key Insights
Cue Biopharma, Inc. (CUE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Strong 5Y sales CAGR of 54.2%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 68.2% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CUE Price & Volume
Cue Biopharma, Inc. (CUE) stock price & volume — 10-year historical chart
Loading chart...
CUE Growth Metrics
Cue Biopharma, Inc. (CUE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years54.16%
3 Years180.46%
TTM195.75%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM34.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM57.56%
Return on Capital
10 Years-79.94%
5 Years-91.19%
3 Years-109.43%
Last Year-112.46%
CUE Peer Comparison
Cue Biopharma, Inc. (CUE) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 AGIO | 1.64B | 27.53 | -3.87 | 48.03% | -6.4% | -34.11% | 0.05 | |
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.5B | 24.80 | -7.54 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 6.87B | 43.03 | 15.53 | 87.32% | 65.95% | 87.36% | 0.40 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare CUE vs Peers
Cue Biopharma, Inc. (CUE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CUE Income Statement
Cue Biopharma, Inc. (CUE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 1.14M | 3.46M | 3.15M | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Revenue Growth % | - | - | 202.67% | -8.79% | 373.68% | -91.67% | 340.96% | 69.16% | 195.75% |
| Cost of Goods Sold | 419.57K | 28.54M | 27.49M | 33.55M | -1.78M | 0 | 38.1M | 0 | 3.48M |
| COGS % of Revenue | - | 2498.16% | 794.82% | 1063.48% | -11.9% | - | 693.93% | - | 12.67% |
| Gross Profit | -419.57K▲ 0% | -27.4M▼ 6430.9% | -24.03M▲ 12.3% | -30.39M▼ 26.5% | 16.72M▲ 155.0% | 1.25M▼ 92.6% | -32.61M▼ 2719.0% | 9.29M▲ 128.5% | 23.99M▲ 158.3% |
| Gross Margin % | - | -2398.16% | -694.82% | -963.48% | 111.9% | 100% | -593.93% | 100% | 87.33% |
| Gross Profit Growth % | -107.62% | -6430.87% | 12.31% | -26.48% | 155.01% | -92.55% | -2719.04% | 128.48% | 158.28% |
| Operating Expenses | 23.23M | 39.84M | 12.74M | 14.65M | 60.43M | 54.47M | 19.54M | 50.79M | 50.51M |
| OpEx % of Revenue | - | 3486.71% | 368.39% | 464.48% | 404.46% | 4375.1% | 355.96% | 546.86% | 183.89% |
| Selling, General & Admin | 4.33M | 11.3M | 12.74M | 14.65M | 17.31M | 16.17M | 16.68M | 14.59M | 16.24M |
| SG&A % of Revenue | - | 988.55% | 368.39% | 464.48% | 115.83% | 1298.71% | 303.83% | 157.05% | 59.14% |
| Research & Development | 18.9M | 28.54M | 27.49M | 33.55M | 41.35M | 38.58M | 40.8M | 36.3M | 37.74M |
| R&D % of Revenue | - | 2498.16% | 794.82% | 1063.48% | 276.73% | 3098.63% | 743.21% | 390.82% | 137.42% |
| Other Operating Expenses | 0 | 165.34K | -27.49M | -33.55M | 1.78M | -277K | -37.94M | -93K | -3.48M |
| Operating Income | -23.23M▲ 0% | -38.7M▼ 66.6% | -36.77M▲ 5.0% | -45.04M▼ 22.5% | -43.71M▲ 3.0% | -53.23M▼ 21.8% | -52.15M▲ 2.0% | -41.5M▲ 20.4% | -26.55M▲ 36.0% |
| Operating Margin % | - | -3386.71% | -1063.21% | -1427.96% | -292.56% | -4275.1% | -949.89% | -446.86% | -96.67% |
| Operating Income Growth % | -203.38% | -66.55% | 4.98% | -22.5% | 2.95% | -21.76% | 2.02% | 20.42% | 36.02% |
| EBITDA | -22.81M | -37.94M | -35.96M | -43.99M | -45.49M | -51.42M | -48.71M | -39.15M | -23.07M |
| EBITDA Margin % | - | -3320.19% | -1039.76% | -1394.44% | -304.46% | -4130.04% | -887.3% | -421.56% | -84% |
| EBITDA Growth % | -205.98% | -66.28% | 5.21% | -22.32% | -3.42% | -13.03% | 5.26% | 19.63% | 41.07% |
| D&A (Non-Cash Add-back) | 419.57K | 760.01K | 810.78K | 1.06M | -1.78M | 1.81M | 3.44M | 2.35M | 3.48M |
| EBIT | -23.23M | -38.7M | -36.77M | -45.04M | -43.67M | -52.3M | -49.49M | -39.88M | -26.52M |
| Net Interest Income | 0 | 376.01K | 482.79K | 463.91K | 45.9K | 215K | 1.42M | 826K | 450K |
| Interest Income | 35 | 376.01K | 419K | 463.91K | 45.9K | 928.24K | 2.66M | 1.62M | 807K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 713.82K | 1.25M | 796K | 357K |
| Other Income/Expense | 35 | 541.35K | 482.79K | 463.91K | 45.9K | 215K | 1.42M | 826K | 419K |
| Pretax Income | -23.23M▲ 0% | -38.16M▼ 64.2% | -36.29M▲ 4.9% | -44.58M▼ 22.9% | -43.67M▲ 2.0% | -53.01M▼ 21.4% | -50.73M▲ 4.3% | -40.67M▲ 19.8% | -26.1M▲ 35.8% |
| Pretax Margin % | - | -3339.33% | -1049.25% | -1413.26% | -292.25% | -4257.83% | -924.1% | -437.97% | -95.03% |
| Income Tax | 0 | 825K | 412.5K | 206.25K | 495K | 0 | 0 | 0 | 500K |
| Effective Tax Rate % | 0% | -2.16% | -1.14% | -0.46% | -1.13% | 0% | 0% | 0% | -1.92% |
| Net Income | -23.23M▲ 0% | -38.98M▼ 67.8% | -36.7M▲ 5.9% | -44.78M▼ 22.0% | -44.16M▲ 1.4% | -53.01M▼ 20.0% | -50.73M▲ 4.3% | -40.67M▲ 19.8% | -26.6M▲ 34.6% |
| Net Margin % | - | -3411.53% | -1061.18% | -1419.79% | -295.56% | -4257.83% | -924.1% | -437.97% | -96.85% |
| Net Income Growth % | -203.38% | -67.77% | 5.85% | -22.03% | 1.39% | -20.04% | 4.3% | 19.83% | 34.6% |
| Net Income (Continuing) | -23.23M | -38.98M | -36.7M | -44.78M | -44.16M | -53.01M | -50.73M | -40.67M | -26.6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -33.90▲ 0% | -58.20▼ 71.7% | -49.80▲ 14.4% | -46.80▲ 6.0% | -42.30▲ 9.6% | -44.70▼ 5.7% | -33.30▲ 25.5% | -21.60▲ 35.1% | -8.40▲ 61.1% |
| EPS Growth % | -205.41% | -71.68% | 14.43% | 6.02% | 9.62% | -5.67% | 25.5% | 35.14% | 61.11% |
| EPS (Basic) | -33.90 | -58.20 | -49.80 | -46.80 | -42.30 | -44.70 | -33.30 | -21.60 | -8.40 |
| Diluted Shares Outstanding | 688.02K | 671.13K | 734.73K | 956.29K | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
| Basic Shares Outstanding | 688.02K | 671.13K | 734.73K | 956.29K | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CUE Balance Sheet
Cue Biopharma, Inc. (CUE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 65.07M | 40.61M | 61.02M | 87.53M | 68.47M | 77.19M | 51.45M | 25.14M | 36.98M |
| Cash & Short-Term Investments | 63.58M | 39.21M | 59.41M | 84.87M | 64.37M | 76.29M | 48.51M | 23.39M | 27.14M |
| Cash Only | 63.53M | 20.8M | 44.29M | 74.87M | 64.37M | 51.61M | 48.51M | 22.46M | 27.14M |
| Short-Term Investments | 50.07K | 18.41M | 15.12M | 10M | 0 | 24.68M | 0 | 929K | 0 |
| Accounts Receivable | 0 | 0 | 754.9K | 1.42M | 3.14M | 57K | 1.7M | 945K | 7.45M |
| Days Sales Outstanding | - | - | 79.67 | 164.02 | 76.77 | 16.71 | 112.89 | 37.14 | 98.94 |
| Inventory | 225.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 196.17 | - | - | - | - | - | - | - | - |
| Other Current Assets | 453.49K | 104.07K | 0 | 0 | 0 | 841K | 1.24M | 0 | 2.4M |
| Total Non-Current Assets | 1.89M | 4.75M | 10.58M | 12.01M | 14.93M | 14.1M | 10.08M | 7.05M | 5.23M |
| Property, Plant & Equipment | 1.69M | 2.78M | 7.18M | 8.88M | 11.92M | 10.7M | 7.12M | 4.84M | 4.32M |
| Fixed Asset Turnover | - | 0.41x | 0.48x | 0.36x | 1.25x | 0.12x | 0.77x | 1.92x | 6.37x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 175K | 0 | 11.67K | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 150K | 0 | 0 | 150K | 0 | 151K | 0 | 154K |
| Other Non-Current Assets | 23.28K | 1.82M | 3.38M | 3.12M | 2.86M | 3.39M | 2.81M | 2.21M | 760K |
| Total Assets | 66.95M▲ 0% | 45.36M▼ 32.2% | 71.61M▲ 57.8% | 99.53M▲ 39.0% | 83.4M▼ 16.2% | 91.28M▲ 9.5% | 61.53M▼ 32.6% | 32.19M▼ 47.7% | 42.21M▲ 31.1% |
| Asset Turnover | - | 0.03x | 0.05x | 0.03x | 0.18x | 0.01x | 0.09x | 0.29x | 0.65x |
| Asset Growth % | 311.3% | -32.25% | 57.85% | 39% | -16.21% | 9.45% | -32.59% | -47.68% | 31.13% |
| Total Current Liabilities | 5.35M | 6.22M | 11.66M | 16.32M | 12.79M | 11.55M | 17.08M | 13.69M | 13.49M |
| Accounts Payable | 1.33M | 2.04M | 882.67K | 2.07M | 2.59M | 2.73M | 3.5M | 2.82M | 3.95M |
| Days Payables Outstanding | 1.16K | 26.03 | 11.72 | 22.53 | -531.84 | - | 33.54 | - | 414.09 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 1.97M | 1.96M | 3.96M | 4.33M | 0 |
| Deferred Revenue (Current) | 623.85K | 2.01M | 0 | 6.68M | 645.35K | 0 | 2.11M | 0 | 0 |
| Other Current Liabilities | 2.54M | 1.58M | 4.1M | 1.96M | 38.31K | 2.27M | 1.92M | 85K | 7.63M |
| Current Ratio | 12.17x | 6.53x | 5.24x | 5.36x | 5.35x | 6.68x | 3.01x | 1.84x | 2.74x |
| Quick Ratio | 12.13x | 6.53x | 5.24x | 5.36x | 5.35x | 6.68x | 3.01x | 1.84x | 2.74x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 5.17M | 5.37M | 4.31M | 5.12M | 14.05M | 7.36M | 1M | 2.29M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 8.04M | 4.2M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 1.35M | 2.37M | 5.12M | 6.02M | 3.16M | 1M | 2.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 4.02M | 0 | 0 | 0 | 0 | 1 | 0 |
| Total Liabilities | 5.35M | 11.39M | 17.02M | 20.62M | 17.91M | 25.6M | 24.45M | 14.69M | 15.78M |
| Total Debt | 2.5M | 0 | 5.8M | 7.15M | 12.02M | 19.32M | 14.7M | 8.88M | 4.2M |
| Net Debt | -61.03M | -20.8M | -38.49M | -67.72M | -52.35M | -32.3M | -33.82M | -13.58M | -22.94M |
| Debt / Equity | 0.04x | - | 0.11x | 0.09x | 0.18x | 0.29x | 0.40x | 0.51x | 0.16x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | -73.26x | -39.75x | -50.10x | -74.29x |
| Total Equity | 61.61M▲ 0% | 33.97M▼ 44.9% | 54.58M▲ 60.7% | 78.91M▲ 44.6% | 65.49M▼ 17.0% | 65.68M▲ 0.3% | 37.09M▼ 43.5% | 17.5M▼ 52.8% | 26.43M▲ 51.0% |
| Equity Growth % | 305.99% | -44.86% | 60.68% | 44.57% | -17.01% | 0.29% | -43.54% | -52.81% | 51.05% |
| Book Value per Share | 89.54 | 50.62 | 74.29 | 82.52 | 62.80 | 55.27 | 24.32 | 9.32 | 8.37 |
| Total Shareholders' Equity | 61.61M | 33.97M | 54.58M | 78.91M | 65.49M | 65.68M | 37.09M | 17.5M | 26.43M |
| Common Stock | 20.13K | 20.7K | 26.56K | 30.35K | 32.2K | 43K | 47K | 62K | 97K |
| Retained Earnings | -32.82M | -71.8M | -108.5M | -153.29M | -197.45M | -250.46M | -301.19M | -341.86M | -368.47M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -661.15K | -10.96K | -10.32K | 7.13K | 0 | -96K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CUE Cash Flow Statement
Cue Biopharma, Inc. (CUE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.19M | -26.41M | -30.8M | -32.49M | -38.84M | -41.81M | -39.96M | -36.33M | -21.69M |
| Operating CF Margin % | - | -2311.47% | -890.51% | -1030.14% | -259.93% | -3357.91% | -727.89% | -391.18% | -78.96% |
| Operating CF Growth % | -104.27% | -116.63% | -16.61% | -5.51% | -19.52% | -7.64% | 4.41% | 9.09% | 40.3% |
| Net Income | -23.23M | -38.98M | -36.7M | -44.78M | -44.16M | -53.01M | -50.73M | -40.67M | -26.6M |
| Depreciation & Amortization | 419.57K | 760.01K | 5.17M | -3.15M | -1.78M | 1.81M | 3.44M | 2.35M | 958K |
| Stock-Based Compensation | 2.78M | 7.17M | 6.52M | 10.48M | 11.52M | 9.5M | 8.18M | 6.85M | 4.74M |
| Deferred Taxes | 10.68K | 79.86K | -18.19K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.93M | 345.1K | -4.28M | -479.54K | -26.13K | -454K | 90K | 74K | 2.51M |
| Working Capital Changes | 2.91M | 4.21M | -1.49M | 5.43M | -4.39M | 356K | -934K | -4.92M | -3.29M |
| Change in Receivables | 0 | 0 | -754.9K | -662.58K | -1.73M | 3.08M | -1.64M | 753K | -6.5M |
| Change in Inventory | 0 | 0 | -509.8K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 561.59K | 376.15K | -1.15M | 741.26K | 520.4K | 83K | 770K | -678K | 1.13M |
| Cash from Investing | -1.2M | -20.35M | 3.45M | 4.46M | 9.11M | -24.61M | 25M | 32K | 75K |
| Capital Expenditures | -1.2M | -1.85M | -46.35K | -595.26K | -913.04K | -171K | 0 | -66K | -177K |
| CapEx % of Revenue | - | 162.28% | 1.34% | 18.87% | 6.11% | 13.73% | - | 0.71% | 0.64% |
| Acquisitions | 0 | 0 | 127.5K | 0 | 0 | 0 | 0 | 0 | 40K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -35 | -18.5M | 0 | 0 | 21.55K | 6K | 2K | 98K | 212K |
| Cash from Financing | 62M | 4.18M | 50.79M | 58.61M | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 10M | -2M | -4M | -4.5M |
| Equity Issued (Net) | 62M | 4.17M | 49M | 56.68M | 17.38M | 39.3M | 13.39M | 14.22M | 30.79M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -4.16M | 0 | -91.03K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 9.01K | 12.5K | 1.79M | 1.93M | 1.85M | 4.36M | 473K | 18K | 0 |
| Net Change in Cash | 48.61M▲ 0% | -42.58M▼ 187.6% | 23.44M▲ 155.0% | 30.58M▲ 30.4% | -10.5M▼ 134.3% | -12.76M▼ 21.5% | -3.1M▲ 75.7% | -26.05M▼ 740.7% | 4.68M▲ 118.0% |
| Free Cash Flow | -13.4M▲ 0% | -28.27M▼ 111.0% | -30.84M▼ 9.1% | -33.09M▼ 7.3% | -39.75M▼ 20.1% | -41.98M▼ 5.6% | -39.96M▲ 4.8% | -36.4M▲ 8.9% | -21.86M▲ 39.9% |
| FCF Margin % | - | -2473.75% | -891.85% | -1049.01% | -266.04% | -3371.65% | -727.89% | -391.89% | -79.6% |
| FCF Growth % | -106.6% | -110.99% | -9.12% | -7.28% | -20.13% | -5.6% | 4.8% | 8.92% | 39.93% |
| FCF per Share | -19.47 | -42.12 | -41.98 | -34.60 | -38.12 | -35.33 | -26.20 | -19.38 | -6.92 |
| FCF Conversion (FCF/Net Income) | 0.52x | 0.68x | 0.84x | 0.73x | 0.88x | 0.79x | 0.79x | 0.89x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 570K | 1M | 669K | 0 |
| Taxes Paid | 0 | 825K | 412.5K | 0 | 0 | 0 | 0 | 0 | 0 |
CUE Key Ratios
Cue Biopharma, Inc. (CUE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -69.27% | -60.52% | -81.57% | -82.88% | -67.1% | -61.16% | -80.82% | -98.73% | -149.03% | -121.11% |
| Return on Invested Capital (ROIC) | -1469.1% | -4237.96% | -422.31% | -188.49% | -247.66% | -269.45% | -171.6% | -213.43% | -866.75% | -537.56% |
| Gross Margin | - | - | -2398.16% | -694.82% | -963.48% | 111.9% | 100% | -593.93% | 100% | 87.33% |
| Net Margin | - | - | -3411.53% | -1061.18% | -1419.79% | -295.56% | -4257.83% | -924.1% | -437.97% | -96.85% |
| Debt / Equity | - | 0.04x | - | 0.11x | 0.09x | 0.18x | 0.29x | 0.40x | 0.51x | 0.16x |
| Interest Coverage | - | - | - | - | - | - | -73.26x | -39.75x | -50.10x | -74.29x |
| FCF Conversion | 0.78x | 0.52x | 0.68x | 0.84x | 0.73x | 0.88x | 0.79x | 0.79x | 0.89x | 0.82x |
| Revenue Growth | - | - | - | 202.67% | -8.79% | 373.68% | -91.67% | 340.96% | 69.16% | 195.75% |
CUE Frequently Asked Questions
Cue Biopharma, Inc. (CUE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cue Biopharma, Inc. (CUE) reported $27.5M in revenue for fiscal year 2025.
Cue Biopharma, Inc. (CUE) grew revenue by 195.7% over the past year. This is strong growth.
Cue Biopharma, Inc. (CUE) reported a net loss of $26.6M for fiscal year 2025.
Dividend & Returns
Cue Biopharma, Inc. (CUE) has a return on equity (ROE) of -121.1%. Negative ROE indicates the company is unprofitable.
Cue Biopharma, Inc. (CUE) had negative free cash flow of $21.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More CUE
Cue Biopharma, Inc. (CUE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates